全文获取类型
收费全文 | 663篇 |
免费 | 41篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 18篇 |
妇产科学 | 20篇 |
基础医学 | 56篇 |
口腔科学 | 4篇 |
临床医学 | 60篇 |
内科学 | 250篇 |
皮肤病学 | 2篇 |
神经病学 | 16篇 |
特种医学 | 90篇 |
外科学 | 57篇 |
综合类 | 30篇 |
预防医学 | 32篇 |
眼科学 | 7篇 |
药学 | 24篇 |
肿瘤学 | 44篇 |
出版年
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 7篇 |
2017年 | 14篇 |
2016年 | 10篇 |
2015年 | 10篇 |
2014年 | 10篇 |
2013年 | 16篇 |
2012年 | 33篇 |
2011年 | 21篇 |
2010年 | 25篇 |
2009年 | 18篇 |
2008年 | 23篇 |
2007年 | 37篇 |
2006年 | 31篇 |
2005年 | 29篇 |
2004年 | 29篇 |
2003年 | 26篇 |
2002年 | 14篇 |
2001年 | 15篇 |
2000年 | 17篇 |
1999年 | 10篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 18篇 |
1993年 | 13篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 12篇 |
1987年 | 24篇 |
1986年 | 15篇 |
1985年 | 10篇 |
1984年 | 9篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1978年 | 6篇 |
1974年 | 12篇 |
1973年 | 9篇 |
1972年 | 4篇 |
1971年 | 7篇 |
1970年 | 6篇 |
1969年 | 10篇 |
1968年 | 7篇 |
1967年 | 6篇 |
排序方式: 共有711条查询结果,搜索用时 234 毫秒
1.
2.
3.
4.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献
5.
6.
Braffman BH; Coleman BG; Ramchandani P; Arger PH; Nodine CF; Dinsmore BJ; Louie A; Betsch SE 《Radiology》1994,190(3):797
7.
8.
9.
10.
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis 总被引:37,自引:0,他引:37
Herrington DM Reboussin DM Brosnihan KB Sharp PC Shumaker SA Snyder TE Furberg CD Kowalchuk GJ Stuckey TD Rogers WJ Givens DH Waters D 《The New England journal of medicine》2000,343(8):522-529
BACKGROUND: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. METHODS: We randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (+/-SD) of 3.2+/-0.6 years. Base-line and follow-up coronary angiograms were analyzed by quantitative coronary angiography. RESULTS: Estrogen and estrogen plus medroxyprogesterone acetate produced significant reductions in low-density lipoprotein cholesterol levels (9.4 percent and 16.5 percent, respectively) and significant increases in high-density lipoprotein cholesterol levels (18.8 percent and 14.2 percent, respectively); however, neither treatment altered the progression of coronary atherosclerosis. After adjustment for measurements at base line, the mean (+/-SE) minimal coronary-artery diameters at follow-up were 1.87+/-0.02 mm, 1.84+/-0.02 mm, and 1.87+/-0.02 mm in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively. The differences between the values for the two active-treatment groups and the value for the placebo group were not significant. Analyses of several secondary angiographic outcomes and subgroups of women produced similar results. The rates of clinical cardiovascular events were also similar among the treatment groups. CONCLUSIONS: Neither estrogen alone nor estrogen plus medroxyprogesterone acetate affected the progression of coronary atherosclerosis in women with established disease. These results suggest that such women should not use estrogen replacement with an expectation of cardiovascular benefit. 相似文献